Literature DB >> 9129140

Alternative multivariate modelling for time to local recurrence for breast cancer patients receiving a lumpectomy alone.

J W Chapman1, W Hanna, H J Kahn, H L Lickley, J Wall, E B Fish, D R McCready.   

Abstract

Certain prognostic factors (patient and/or tumour characteristics) may be associated with low (or high) risk for local recurrence. Patients with these characteristics could be candidates for less (or more) adjuvant therapy or a less (or more) aggressive surgical approach. However, the assessment of many factors can be problematic with the standard multivariate technique-a Cox proportional hazards model and step-wise regression. We compared the results obtained when using a Cox model with those from four alternative models (exponential, Weibull, log logistic and log Normal) in step-wise and all subset regressions. Between 1977 and 1986, 293 primary invasive breast cancer patients were treated at the Henrietta Banting Breast Centre with a lumpectomy with or without an axillary dissection, and with no postoperative adjuvant therapy. The variables considered were age, lymph node status, tumour size, estrogen receptor (ER), progesterone receptor (PgR), histologic grade, nuclear grade, carcinoma in situ (CIS), amount of CIS, and presence of tumour emboli. With follow-up to 1991, nodal status was not found to be included in the step-wise Cox model, although it was in the step-wise exponential, Weibull and log Normal models, and in the best all subset models for all model types. The variables tumour emboli, ER, age, CIS and nodal status were consistently included in the best all subset regressions, regardless of model type. In the 1993 follow-up, the variables in the step-wise Cox model were tumour emboli, ER, age, CIS and nodal status. The multivariate consideration of all possible subsets of regression variables led to an earlier indication of the importance of nodal status, while the data strongly supported accelerated failure time models over the Cox model.

Entities:  

Mesh:

Year:  1996        PMID: 9129140     DOI: 10.1016/s0960-7404(96)80031-4

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  3 in total

1.  Multimodality therapy for locoregional extrahepatic cholangiocarcinoma: a population-based analysis.

Authors:  Clifton D Fuller; Samuel J Wang; Mehee Choi; Brian G Czito; John Cornell; Tania M Welzel; Katherine A McGlynn; Join Y Luh; Charles R Thomas
Journal:  Cancer       Date:  2009-11-15       Impact factor: 6.860

2.  Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours.

Authors:  Daniel M Huse; Margaret von Mehren; Gregory Lenhart; Heikki Joensuu; Charles Blanke; Weiwei Feng; Stan Finkelstein; George Demetri
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

3.  Competing risks analyses for recurrence from primary breast cancer.

Authors:  J W Chapman; E B Fish; M A Link
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.